Equity securities

(HRC): Johnson Fistel Investigates Proposed Sale of Hill-Rom; Are Shareholders Getting a Fair Deal?

Retrieved on: 
Saturday, September 4, 2021

The investigation concerns whether the Hill-Rom board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Hill-Rom shares of common stock.

Key Points: 
  • The investigation concerns whether the Hill-Rom board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Hill-Rom shares of common stock.
  • Nationally recognized, Johnson Fistel is investigating whether the proposed deal represents adequate consideration.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia.
  • The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits.

Acquisition of Common Shares of StageZero Life Sciences Ltd.

Retrieved on: 
Saturday, September 4, 2021

Toronto, Ontario--(Newsfile Corp. - September 3, 2021) - Health Clinics Limited ("HCL") announced today that it has acquired ownership and control of an aggregate of 12,400,000 common shares ("Common Shares") in the capital of StageZero Life Sciences Ltd. (the "Company").

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 3, 2021) - Health Clinics Limited ("HCL") announced today that it has acquired ownership and control of an aggregate of 12,400,000 common shares ("Common Shares") in the capital of StageZero Life Sciences Ltd. (the "Company").
  • HCL acquired 12,400,000 common shares in the capital of the Company (the "Acquisition Shares"), pursuant to a share purchase agreement (the "Purchase Agreement") entered into by the Company, HCL, Health Clinics USA, Corp., Care Oncology, Inc., and Care Oncology Physicians, PC, whereby the Company purchased all of the issued and outstanding shares of Clinics Operations Limited, a wholly-owned subsidiary of HCL, as consideration for the Acquisition Shares (the "Transaction").
  • The Acquisition Shares represent 15.72% of the issued and outstanding common shares of the Company (including the Acquisition Shares, as of September 2, 2021, there were a total of 78,858,281 common shares of the Company issued and outstanding).
  • A further 8,000,000 common shares are issuable by the Corporation to HCL contingent upon the achievement of certain milestones and shareholder approval.

iSIGN Media Announces the Close of its Previously Announced Private Placement of up to $1.2 million

Retrieved on: 
Friday, September 3, 2021

With this Final Tranche, the Company has received funds totaling $832,510 and has issued a total of 16,650,200 Units (Units) at a price of $0.05 per Unit.

Key Points: 
  • With this Final Tranche, the Company has received funds totaling $832,510 and has issued a total of 16,650,200 Units (Units) at a price of $0.05 per Unit.
  • The proceeds of the Placement will be for new software development and enhancements to existing technologies and operational purposes.
  • The forward-looking statements are not historical facts but reflect iSIGN Medias current expectations regarding future results or events.
  • iSIGN Media assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Xigem Technologies Announces Shares for Debt Transaction and Warrant Exercise

Retrieved on: 
Friday, September 3, 2021

The Shares will be subject to a four-month hold period in accordance with applicable securities laws.

Key Points: 
  • The Shares will be subject to a four-month hold period in accordance with applicable securities laws.
  • All share issuances are subject to applicable regulatory approval, including the approval of the Canadian Securities Exchange.
  • The Company also announced the recent exercise of certain warrants at an exercise price of $0.07 per common share of Xigem (the "Warrants").
  • To date, 2,275,000 Warrants have been exercised for gross proceeds of $159,250.

Arbor Realty Trust, Inc. Announces Pricing of Public Offering of Series E Cumulative Redeemable Preferred Stock

Retrieved on: 
Wednesday, August 4, 2021

UNIONDALE, N.Y., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (the Company) (NYSE:ABR) announced today that it has priced the public offering of 5,000,000 shares of its 6.25% Series E Cumulative Redeemable Preferred Stock (the Series E Preferred Stock), liquidation preference $25.00 per share, for gross proceeds of $125 million, before deducting underwriting discounts and estimated offering expenses.

Key Points: 
  • UNIONDALE, N.Y., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (the Company) (NYSE:ABR) announced today that it has priced the public offering of 5,000,000 shares of its 6.25% Series E Cumulative Redeemable Preferred Stock (the Series E Preferred Stock), liquidation preference $25.00 per share, for gross proceeds of $125 million, before deducting underwriting discounts and estimated offering expenses.
  • The Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of the Series E Preferred Stock to cover over-allotments, if any.
  • The Company intends to use the net proceeds from the offering to make investments relating to its business and for general corporate purposes.
  • The offering of these securities is being made only by means of a prospectus and related prospectus supplement.

RxSight, Inc. Announces Closing of Initial Public Offering and Partial Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Wednesday, August 4, 2021

With the addition of the partial exercise of the underwriters option to purchase additional shares, the total number of shares sold by RxSight in the offering increased to 8,248,594 shares of common stock, and the aggregate gross proceeds to RxSight before deducting underwriting discounts and commissions and offering expenses, were approximately $132 million.

Key Points: 
  • With the addition of the partial exercise of the underwriters option to purchase additional shares, the total number of shares sold by RxSight in the offering increased to 8,248,594 shares of common stock, and the aggregate gross proceeds to RxSight before deducting underwriting discounts and commissions and offering expenses, were approximately $132 million.
  • Shares of RxSights common stock began trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol RXST.
  • J.P. Morgan Securities LLC and BofA Securities, Inc. acted as joint book-running managers of the offering and as representatives of the underwriters.
  • This press release contains forward-looking statements, including with respect to the proposed initial public offering.

Stifel Declares Quarterly Common Stock Cash Dividend and Declares Preferred Stock Cash Dividend

Retrieved on: 
Wednesday, August 4, 2021

The Board of Directors also declared a quarterly cash dividend on the outstanding shares of its 6.25% Non-Cumulative Perpetual Preferred Stock, Series B (the Series B Preferred Stock), 6.125% Non-Cumulative Perpetual Preferred Stock, Series C (the Series C Preferred Stock), and 4.50% Non-Cumulative Perpetual Preferred Stock, Series D (the Series D Preferred Stock).

Key Points: 
  • The Board of Directors also declared a quarterly cash dividend on the outstanding shares of its 6.25% Non-Cumulative Perpetual Preferred Stock, Series B (the Series B Preferred Stock), 6.125% Non-Cumulative Perpetual Preferred Stock, Series C (the Series C Preferred Stock), and 4.50% Non-Cumulative Perpetual Preferred Stock, Series D (the Series D Preferred Stock).
  • The declared cash dividend on the Series B Preferred Stock and Series C Preferred Stock is for the period from June 15, 2021, up to, but excluding, September 15, 2021.
  • The declared cash dividend equated to approximately $0.390625 per depositary share, or $390.625 per share of the Series B Preferred Stock outstanding.
  • The declared cash dividend equated to approximately $0.3828125 per depositary share, or $382.8125 per share of the Series C Preferred Stock Outstanding.

ADM Directors Declare Cash Dividend

Retrieved on: 
Wednesday, August 4, 2021

ADMs (NYSE: ADM) Board of Directors has declared a cash dividend of 37.0 cents per share on the companys common stock.

Key Points: 
  • ADMs (NYSE: ADM) Board of Directors has declared a cash dividend of 37.0 cents per share on the companys common stock.
  • The dividend is payable on Sept. 8, 2021, to shareholders of record on Aug. 18, 2021.
  • As of June 30, 2021, there were 559,360,690 shares of ADM common stock outstanding.
  • At ADM, we unlock the power of nature to provide access to nutrition worldwide.

Transaction in own shares

Retrieved on: 
Wednesday, August 4, 2021

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Arix intends to retain the purchased shares in treasury.
  • Following settlement of the above purchase, Arix will have 130,828,800 ordinary shares of 0.001 pence each in issue (excluding 4,780,853 ordinary shares of 0.001p each held in treasury).
  • In accordance with Article 5(1)(b) of Regulation (EU) No.

SQUARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SQ and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, August 4, 2021

On August 1, 2021, Square announced that it had entered into an agreement to merge with Afterpay in a deal valued at approximately $29 billion.

Key Points: 
  • On August 1, 2021, Square announced that it had entered into an agreement to merge with Afterpay in a deal valued at approximately $29 billion.
  • Pursuant to the merger agreement, Afterpay stockholders will receive 0.375 shares of Square common stock for each share of Afterpay common stock owned.
  • Bragar Eagel & Squire is concerned that Squares board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.